Received Apr 20, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | T7P7Y | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 37F34 | — |
Administration after Excursion; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a 11-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number 37F34, expiry date 24-OCT-2027) for prophylaxis. Co-suspect products included Men ACWY-CRM NVS (Menveo) (batch number T7P7Y, expiry date 31-JAN-2027) for prophylaxis. On an unknown date, the patient received Boostrix and Menveo. On an unknown date, an unknown time after receiving Boostrix and Menveo, the patient experienced incorrect storage of drug (Verbatim: Administration after Excursion). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date 09-APR-2026 A healthcare professional called in to initially report that their GSK vaccines had unfortunately been exposed to a temperature excursion. The vaccine administration facility was the same as primary reporter. This case has been linked with case US2026049941 reported by same reporter.; Sender's Comments: US-GSK-US2026049941:SAME REPORTER